Singapore Attracts Pharmaceutical Manufacturing Investment - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

Singapore Attracts Pharmaceutical Manufacturing Investment
Singapore moves forward with a plan to diversify its life science investment with projects in biologics and drug discovery.

Pharmaceutical Technology
Volume 32, Issue 1

Biotechnology investment in Singapore

As the pharmaceutical industry shifts its emphasis to biologics, Singapore is also keeping pace to build its biopharmaceutical base. "Having established a reputation as one of the world's most competitive and trusted sites for producing small-molecule-based active pharmaceutical ingredients and final dosage forms, Singapore is now aggressively pursuing biologics manufacturing investments, especially since biologics is anticipated to be a key growth driver for the global industry," say Yeoh. "We are quickly building up a critical mass of biologics manufacturing investments and expect to maintain this momentum as we attract more companies to set up such manufacturing facilities there." He points to five major biologics manufacturing investments (Lonza, GSK Biologicals, Genentech, and Novartis) that total more than US$1.5 billion.

Yeoh points out the first phase of Singapore's BMS initiative, which was from 2000-2005, focused on putting key building blocks by establishing core capabilities in biomedical research and introducing human and industrial capital. "For the next phase (2006-2010), we are building on this foundation and strengthening our capabilities in translational and clinical research to bring discoveries from the bench to the bedside and the marketplace and ultimately improve human healthcare," says Yeoh. That effort involves further expansion of its industry R&D base and an increase in the number of companies undertaking the discovery and development of new drugs and medical devices in Singapore.

For more on this topic, see:

Manufacturing Investment in Puerto Rico

Pharmaceutical and Biopharmaceutical Manufacturing Advances in Ireland


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Source: Pharmaceutical Technology,
Click here